Further options for your experiments:
Application schemes and assay conditions can be adapted to your needs.
Whole-cell recordings or single-channel analysis in various expression systems
(HEK 293, CHO, Neuroblastoma etc.) can be conducted to test the effects of drugs on voltage-gated or ligand-gated ion channels.
B'SYS currently operates 4 automated patch clamp devices (Sophion Qpatch™).
Please contact us for details or offers → Contact
| Target | Gene | Species | Disorder | Manual | Automated | ||
|---|---|---|---|---|---|---|---|
| KV1.1 | KCNA1 | human | Seizure disorders | 0 | 0 |
|
 |
| KV1.2 | KCNA2 | human | Seizure disorders | 0 | 0 |
|
|
| KV1.3 | KCNA3 | human | Immune system related | 0 | 0 |
|
|
| KV1.4 | KCNA4 | human | Autoimmune diseases | 0 | 0 | |
|
| KV1.5 | KCNA5 | human | Heart function | 0 | 0 |
|
|
| KV1.6 | KCNA6 | human | Seizure disorders | 0 | 0 | |
|
| KV1.7 | KCNA7 | human | Heart function | 0 | 0 | |
|
| KV2.1 | KCNB1 | human | Seizure disorders | 0 | 0 |
|
|
| KV2.1 | KCNB1 | human | Seizure disorders | 0 | 0 |
|
|
| KV2.2 | KCNB2 | human | Seizure disorders | 0 | 0 | |
|
| KV2.2 | KCNB2 | human | Seizure disorders | 0 | 0 | |
|
| KV3.1a (short) | KCNC1 | human | Autism / Epilepsy / Pain / Psychiatric Disorders | 0 | 0 | |
|
| KV3.1b (long) | KCNC1 | human | Autism / Epilepsy / Pain / Psychiatric Disorders | 0 | 0 | |
|
| KV3.2 | KCNC2 | human | Epilepsy / Pain / Psychiatric Disorders | 0 | 1 | |
|
| KV3.3 | KCNC3 | human | Hearing disorders / Spinocerebellar ataxia | 0 | 1 | |
|
| KV3.4 | KCNC4 | human | Neurodegeneration | 0 | 1 | |
|
| KV4.2 | KCND2 | human | Seizure disorders | 0 | 1 | |
|
| KV4.3 | KCND3 | human | Heart function | 0 | 0 | |
|
| KV4.3 | KCND3 | human | Heart function | 0 | 1 | |
|
| KV4.3 KChip | KCND3 | human | Heart function | 0 | 0 | |
|
| KV7.1 (KVLQT1) / minK | KCNQ1 / KCNE1 | human | LQT Syndrome | 0 | 0 | |
|
| KV7.1 (KVLQT1) | KCNQ1 | human | LQT Syndrome | 0 | 1 | |
|
| KV7.1 (KVLQT1) | KCNQ1 | human | LQT Syndrome | 0 | 1 | |
|
| KV7.1 (KVLQT1) | KCNQ1 | human | LQT Syndrome 1/5 | 0 | 1 | |
|
| KV7.1 (KVLQT1) / minK | KCNQ1/KCNE1 | human | LQT Syndrome 1/5 | 0 | 0 |
|
|
| KV7.1 (KVLQT1) / minK | KCNQ1/KCNE1 | human | LQT Syndrome 1/5 | 0 | 0 |
|
|
| KV7.1 (KVLQT1) / minK / steady state current | KCNQ1/KCNE1 | human | LQT Syndrome 1/5 | 0 | 1 |
|
|
| KV7.2 | KCNQ2 | human | Epilepsy | 0 | 1 |
|
|
| KV7.3 | KCNQ3 | human | Epilepsy | 0 | 1 | |
|
| KV7.2/3 | KCNQ2 / KCNQ3 | rat | Epilepsy | 0 | 0 | |
|
| KV7.2/3 | KCNQ2 / KCNQ3 | human | Epilepsy | 0 | 0 | |
|
| KV10.1 | KCNH1 | human | Cancer | 0 | 1 |
|
|
| KV11.1 (hERG DUO) | KCNH2 | human | LQT Syndrome 2 | 0 | 0 |
|
|
| KV11.1 (hERG) / trafficking | KCNH2 | human | LQT Syndrome 2 | 0 | 0 | |
|
| KV11.1 (hERG) / peak tail current | KCNH2 | human | LQT Syndrome 2 | 0 | 1 | |
|
| KV11.1 (hERG) | KCNH2 | human | LQT Syndrome 2 | 0 | 0 | |
|
| KV11.1 (hERG) | KCNH2 | human | LQT Syndrome 2 | 0 | 0 | |
|
| KV11.1 (hERG) | KCNH2 | human | LQT Syndrome 2 | 0 | 0 | |
|
| KV11.1 (hERG) | KCNH2 | human | LQT Syndrome 2 | 0 | 0 | |
|
| Kir1.1 | KCNJ1 | human | 0 | 0 | |
||
| Kir2.1 | KCNJ2 | human | LQT Syndrome | 0 | 0 | |
|
| Kir2.3 | KCNJ4 | human | LQT Syndrome 9 | 0 | 1 | |
|
| Kir2.3 | KCNJ4 | human | LQT Syndrome 9 | 0 | 1 | |
|
| Kir3.1 | KCNJ3 | human | 0 | 1 | |
||
| Kir3.4 | KCNJ5 | human | 0 | 1 | |
||
| BK α1 | KCNMA1 | human | Epilepsy / Pain | 0 | 0 | |
|
| BK α1β2 | KCNMA1 / KCNMB2 | human | Autism / Seizure disorders | 0 | 0 |
|
|
| SK1, KCa2.1 | KCNN1 | human | 0 | 1 | |
||
| SK2, KCa2.2 | KCNN2 | human | Heart function / Seizure disorders | 0 | 1 |
|
|
| SK4, KCa3.1 | KCNN4 | human | Heart function | 0 | 1 |
|
|
| K2P18.1 | KCNK18 | human | Pain | 0 | 0 |
|
|
| KCa4.1 | KCNT1 | human | Seizure disorders | 0 | 1 | |
|
| K2P1.1 | KCNK1 | human | 0 | 1 | |
||
| Neuroblastoma whole potassium channels (N1E-115) | 0 | 1 | |